Monoamine oxidase-B inhibition in Alzheimer's disease
Identifieur interne : 000E45 ( PascalFrancis/Corpus ); précédent : 000E44; suivant : 000E46Monoamine oxidase-B inhibition in Alzheimer's disease
Auteurs : Peter Riederer ; Walter Danielczyk ; Edna GrünblattSource :
- Neurotoxicology : (Park Forest South) [ 0161-813X ] ; 2004.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
| pA |
|
|---|
Format Inist (serveur)
| NO : | PASCAL 04-0191604 INIST |
|---|---|
| ET : | Monoamine oxidase-B inhibition in Alzheimer's disease |
| AU : | RIEDERER (Peter); DANIELCZYK (Walter); GRÜNBLATT (Edna); NICOTRA (A.); PARVEZ (S. H.); GLOVER (V.); SANDLER (M.); PARVEZ (S.); MINAMI (M.) |
| AF : | Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15/97080 Würzburg/Allemagne (1 aut., 3 aut.); Ludwig Boltzmann Institute of Clinical Neurobiology/Vienna/Autriche (2 aut.); Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32/00198 Rome/Italie (1 aut.); Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS/91190 Gif sur Yvette/France (2 aut., 5 aut.); Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road/London, W12 ONN/Royaume-Uni (3 aut., 4 aut.); The Research Institute of Personalized Health, Health Sciences University of Hokkaido/061-0293 Ishikari-Tobetsu/Japon (6 aut.) |
| DT : | Publication en série; Niveau analytique |
| SO : | Neurotoxicology : (Park Forest South); ISSN 0161-813X; Etats-Unis; Da. 2004; Vol. 25; No. 1-2; Pp. 271-277; Bibl. 2 p.1/2 |
| LA : | Anglais |
| EA : | Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD. |
| CC : | 002A25; 002B03; 002B17 |
| FD : | Amine oxidase (flavin-containing); Inhibition; Inhibiteur; Démence Alzheimer; Neurologie; Toxicologie |
| FG : | Oxidoreductases; Enzyme; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie |
| ED : | Amine oxidase (flavin-containing); Inhibition; Inhibitor; Alzheimer disease; Neurology; Toxicology |
| EG : | Oxidoreductases; Enzyme; Cerebral disorder; Degenerative disease; Central nervous system disease; Nervous system diseases |
| SD : | Amine oxidase (flavin-containing); Inhibición; Inhibidor; Demencia Alzheimer; Neurología; Toxicología |
| LO : | INIST-18397.354000119285470280 |
| ID : | 04-0191604 |
Links to Exploration step
Pascal:04-0191604Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Monoamine oxidase-B inhibition in Alzheimer's disease</title><author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name><affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1><s2>97080 Würzburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Danielczyk, Walter" sort="Danielczyk, Walter" uniqKey="Danielczyk W" first="Walter" last="Danielczyk">Walter Danielczyk</name><affiliation><inist:fA14 i1="02"><s1>Ludwig Boltzmann Institute of Clinical Neurobiology</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Grunblatt, Edna" sort="Grunblatt, Edna" uniqKey="Grunblatt E" first="Edna" last="Grünblatt">Edna Grünblatt</name><affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1><s2>97080 Würzburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0191604</idno><date when="2004">2004</date><idno type="stanalyst">PASCAL 04-0191604 INIST</idno><idno type="RBID">Pascal:04-0191604</idno><idno type="wicri:Area/PascalFrancis/Corpus">000E45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Monoamine oxidase-B inhibition in Alzheimer's disease</title><author><name sortKey="Riederer, Peter" sort="Riederer, Peter" uniqKey="Riederer P" first="Peter" last="Riederer">Peter Riederer</name><affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1><s2>97080 Würzburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Danielczyk, Walter" sort="Danielczyk, Walter" uniqKey="Danielczyk W" first="Walter" last="Danielczyk">Walter Danielczyk</name><affiliation><inist:fA14 i1="02"><s1>Ludwig Boltzmann Institute of Clinical Neurobiology</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></inist:fA14></affiliation></author><author><name sortKey="Grunblatt, Edna" sort="Grunblatt, Edna" uniqKey="Grunblatt E" first="Edna" last="Grünblatt">Edna Grünblatt</name><affiliation><inist:fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1><s2>97080 Würzburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></inist:fA14></affiliation></author></analytic><series><title level="j" type="main">Neurotoxicology : (Park Forest South)</title><title level="j" type="abbreviated">Neurotoxicology : (Park Forest South)</title><idno type="ISSN">0161-813X</idno><imprint><date when="2004">2004</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Neurotoxicology : (Park Forest South)</title><title level="j" type="abbreviated">Neurotoxicology : (Park Forest South)</title><idno type="ISSN">0161-813X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Alzheimer disease</term><term>Amine oxidase (flavin-containing)</term><term>Inhibition</term><term>Inhibitor</term><term>Neurology</term><term>Toxicology</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Amine oxidase (flavin-containing)</term><term>Inhibition</term><term>Inhibiteur</term><term>Démence Alzheimer</term><term>Neurologie</term><term>Toxicologie</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.</div></front></TEI><inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0161-813X</s0></fA01><fA03 i2="1"><s0>Neurotoxicology : (Park Forest South)</s0></fA03><fA05><s2>25</s2></fA05><fA06><s2>1-2</s2></fA06><fA08 i1="01" i2="1" l="ENG"><s1>Monoamine oxidase-B inhibition in Alzheimer's disease</s1></fA08><fA09 i1="01" i2="1" l="ENG"><s1>Monoamine Oxidases: Molecular, Pharmacological and Neurotoxicological Aspects. A Tribute to Prof. Merton Sandler</s1></fA09><fA11 i1="01" i2="1"><s1>RIEDERER (Peter)</s1></fA11><fA11 i1="02" i2="1"><s1>DANIELCZYK (Walter)</s1></fA11><fA11 i1="03" i2="1"><s1>GRÜNBLATT (Edna)</s1></fA11><fA12 i1="01" i2="1"><s1>NICOTRA (A.)</s1><s9>ed.</s9></fA12><fA12 i1="02" i2="1"><s1>PARVEZ (S. H.)</s1><s9>ed.</s9></fA12><fA12 i1="03" i2="1"><s1>GLOVER (V.)</s1><s9>ed.</s9></fA12><fA12 i1="04" i2="1"><s1>SANDLER (M.)</s1><s9>ed.</s9></fA12><fA12 i1="05" i2="1"><s1>PARVEZ (S.)</s1><s9>ed.</s9></fA12><fA12 i1="06" i2="1"><s1>MINAMI (M.)</s1><s9>ed.</s9></fA12><fA14 i1="01"><s1>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15</s1><s2>97080 Würzburg</s2><s3>DEU</s3><sZ>1 aut.</sZ><sZ>3 aut.</sZ></fA14><fA14 i1="02"><s1>Ludwig Boltzmann Institute of Clinical Neurobiology</s1><s2>Vienna</s2><s3>AUT</s3><sZ>2 aut.</sZ></fA14><fA15 i1="01"><s1>Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32</s1><s2>00198 Rome</s2><s3>ITA</s3><sZ>1 aut.</sZ></fA15><fA15 i1="02"><s1>Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS</s1><s2>91190 Gif sur Yvette</s2><s3>FRA</s3><sZ>2 aut.</sZ><sZ>5 aut.</sZ></fA15><fA15 i1="03"><s1>Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road</s1><s2>London, W12 ONN</s2><s3>GBR</s3><sZ>3 aut.</sZ><sZ>4 aut.</sZ></fA15><fA15 i1="04"><s1>The Research Institute of Personalized Health, Health Sciences University of Hokkaido</s1><s2>061-0293 Ishikari-Tobetsu</s2><s3>JPN</s3><sZ>6 aut.</sZ></fA15><fA20><s1>271-277</s1></fA20><fA21><s1>2004</s1></fA21><fA23 i1="01"><s0>ENG</s0></fA23><fA43 i1="01"><s1>INIST</s1><s2>18397</s2><s5>354000119285470280</s5></fA43><fA44><s0>0000</s0><s1>© 2004 INIST-CNRS. All rights reserved.</s1></fA44><fA45><s0>2 p.1/2</s0></fA45><fA47 i1="01" i2="1"><s0>04-0191604</s0></fA47><fA60><s1>P</s1></fA60><fA61><s0>A</s0></fA61><fA64 i1="01" i2="1"><s0>Neurotoxicology : (Park Forest South)</s0></fA64><fA66 i1="01"><s0>USA</s0></fA66><fC01 i1="01" l="ENG"><s0>Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.</s0></fC01><fC02 i1="01" i2="X"><s0>002A25</s0></fC02><fC02 i1="02" i2="X"><s0>002B03</s0></fC02><fC02 i1="03" i2="X"><s0>002B17</s0></fC02><fC03 i1="01" i2="X" l="FRE"><s0>Amine oxidase (flavin-containing)</s0><s2>FE</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="ENG"><s0>Amine oxidase (flavin-containing)</s0><s2>FE</s2><s5>01</s5></fC03><fC03 i1="01" i2="X" l="SPA"><s0>Amine oxidase (flavin-containing)</s0><s2>FE</s2><s5>01</s5></fC03><fC03 i1="02" i2="X" l="FRE"><s0>Inhibition</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="ENG"><s0>Inhibition</s0><s5>04</s5></fC03><fC03 i1="02" i2="X" l="SPA"><s0>Inhibición</s0><s5>04</s5></fC03><fC03 i1="03" i2="X" l="FRE"><s0>Inhibiteur</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="ENG"><s0>Inhibitor</s0><s5>07</s5></fC03><fC03 i1="03" i2="X" l="SPA"><s0>Inhibidor</s0><s5>07</s5></fC03><fC03 i1="04" i2="X" l="FRE"><s0>Démence Alzheimer</s0><s5>11</s5></fC03><fC03 i1="04" i2="X" l="ENG"><s0>Alzheimer disease</s0><s5>11</s5></fC03><fC03 i1="04" i2="X" l="SPA"><s0>Demencia Alzheimer</s0><s5>11</s5></fC03><fC03 i1="05" i2="X" l="FRE"><s0>Neurologie</s0><s5>12</s5></fC03><fC03 i1="05" i2="X" l="ENG"><s0>Neurology</s0><s5>12</s5></fC03><fC03 i1="05" i2="X" l="SPA"><s0>Neurología</s0><s5>12</s5></fC03><fC03 i1="06" i2="X" l="FRE"><s0>Toxicologie</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="ENG"><s0>Toxicology</s0><s5>14</s5></fC03><fC03 i1="06" i2="X" l="SPA"><s0>Toxicología</s0><s5>14</s5></fC03><fC07 i1="01" i2="X" l="FRE"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="ENG"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="01" i2="X" l="SPA"><s0>Oxidoreductases</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="FRE"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="ENG"><s0>Enzyme</s0><s2>FE</s2></fC07><fC07 i1="02" i2="X" l="SPA"><s0>Enzima</s0><s2>FE</s2></fC07><fC07 i1="03" i2="X" l="FRE"><s0>Encéphale pathologie</s0><s5>61</s5></fC07><fC07 i1="03" i2="X" l="ENG"><s0>Cerebral disorder</s0><s5>61</s5></fC07><fC07 i1="03" i2="X" l="SPA"><s0>Encéfalo patología</s0><s5>61</s5></fC07><fC07 i1="04" i2="X" l="FRE"><s0>Maladie dégénérative</s0><s5>62</s5></fC07><fC07 i1="04" i2="X" l="ENG"><s0>Degenerative disease</s0><s5>62</s5></fC07><fC07 i1="04" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0><s5>62</s5></fC07><fC07 i1="05" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0><s5>63</s5></fC07><fC07 i1="05" i2="X" l="ENG"><s0>Central nervous system disease</s0><s5>63</s5></fC07><fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0><s5>63</s5></fC07><fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux pathologie</s0><s5>64</s5></fC07><fC07 i1="06" i2="X" l="ENG"><s0>Nervous system diseases</s0><s5>64</s5></fC07><fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervioso patología</s0><s5>64</s5></fC07><fN21><s1>131</s1></fN21><fN82><s1>OTO</s1></fN82></pA></standard><server><NO>PASCAL 04-0191604 INIST</NO><ET>Monoamine oxidase-B inhibition in Alzheimer's disease</ET><AU>RIEDERER (Peter); DANIELCZYK (Walter); GRÜNBLATT (Edna); NICOTRA (A.); PARVEZ (S. H.); GLOVER (V.); SANDLER (M.); PARVEZ (S.); MINAMI (M.)</AU><AF>Neurochemical Laboratory, Clinic for Psychiatry and Psychotherapy, Bayerische Julius-Maximilians-Universität Würzburg, Füchsleinstr. 15/97080 Würzburg/Allemagne (1 aut., 3 aut.); Ludwig Boltzmann Institute of Clinical Neurobiology/Vienna/Autriche (2 aut.); Dept. Animal and Human Biology, University of Rome I, Viale dell'Università 32/00198 Rome/Italie (1 aut.); Institut Alfred Fressard of Neuroscience, Bât5 Parc Chateau, CNRS/91190 Gif sur Yvette/France (2 aut., 5 aut.); Institute of Reproductive and Developmental Biology, Imperial College London, Hammersmith Campus, Du Cane Road/London, W12 ONN/Royaume-Uni (3 aut., 4 aut.); The Research Institute of Personalized Health, Health Sciences University of Hokkaido/061-0293 Ishikari-Tobetsu/Japon (6 aut.)</AF><DT>Publication en série; Niveau analytique</DT><SO>Neurotoxicology : (Park Forest South); ISSN 0161-813X; Etats-Unis; Da. 2004; Vol. 25; No. 1-2; Pp. 271-277; Bibl. 2 p.1/2</SO><LA>Anglais</LA><EA>Alzheimer's disease (AD) is the most common cause of dementia in late life. There is still no clear-cut consensus whether this disease involves genetic or environmental factors or both. There is a great need to find a way to delay the disease, as delaying the onset of the disease will bring a great relieve on social and medical resources. The monoamine oxidase-B (MAO-B) inhibitors were shown to be effective in treating Parkinson's disease and possibly AD, with concomitant extension of life span. This article gives a short review on MAO-B inhibitors and their mechanism for neuroprotective effects in AD.</EA><CC>002A25; 002B03; 002B17</CC><FD>Amine oxidase (flavin-containing); Inhibition; Inhibiteur; Démence Alzheimer; Neurologie; Toxicologie</FD><FG>Oxidoreductases; Enzyme; Encéphale pathologie; Maladie dégénérative; Système nerveux central pathologie; Système nerveux pathologie</FG><ED>Amine oxidase (flavin-containing); Inhibition; Inhibitor; Alzheimer disease; Neurology; Toxicology</ED><EG>Oxidoreductases; Enzyme; Cerebral disorder; Degenerative disease; Central nervous system disease; Nervous system diseases</EG><SD>Amine oxidase (flavin-containing); Inhibición; Inhibidor; Demencia Alzheimer; Neurología; Toxicología</SD><LO>INIST-18397.354000119285470280</LO><ID>04-0191604</ID></server></inist></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 000E45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:04-0191604
|texte= Monoamine oxidase-B inhibition in Alzheimer's disease
}}
| This area was generated with Dilib version V0.6.29. |  |